TAG Expense Bankers Ltd. Challenges Analyst Report on Jaguar Wellness

TAG Expense Bankers Ltd. Challenges Analyst Report on Jaguar Wellness

SAN FRANCISCO, CA / ACCESSWIRE / May possibly 11, 2022 / Jaguar Health and fitness, Inc. (NASDAQ:JAGX) now declared that TAG Expenditure Bankers Ltd. (“TAG”) issued an analyst report right now on the company. The paid report was generated by TAG analyst Chris Wickham. Jaguar Overall health is also covered by other analysts from Cantor Fitzgerald and Ladenburg Thalmann & Co. Inc.

“TAG is an worldwide asset management firm centered in the United Kingdom,” mentioned Lisa Conte, Jaguar Health’s president and CEO. “Paid out investigation reviews are prevalent in the United kingdom and Europe, and Chris also manufactured a paid out investigation report, printed March 31, 2022, on Napo Therapeutics S.p.A., the corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer accessibility in Europe. Jaguar Wellness is the bulk shareholder of Napo Therapeutics.”

TAG Financial investment Bankers’ web site is https://tagbankers.com. The record of analysts that cover Jaguar Well being is obtainable right here on the investor relations part of the firm’s site.

Jaguar Wellbeing paid TAG analyst Chris Wickham a flat, up-entrance charge to deliver the exploration report issued now. All conclusions and opinions contained in the analysis report solely symbolize those of TAG Financial commitment Bankers Ltd at the time of publication, and Jaguar Overall health assumes no obligation for any conclusions and opinions contained in the investigation report. Ahead-on the lookout details or statements in the investigate report have info that is dependent on assumptions, forecasts of long term outcomes, estimates of amounts not but determinable, and therefore involve known and unfamiliar hazards, uncertainties and other factors which could induce the true results, overall performance or achievements of their topic issue to be materially distinctive from recent anticipations.

About Jaguar Wellbeing, Jaguar Animal Overall health, Napo Prescription drugs, & Napo Therapeutics

Jaguar Overall health, Inc. is a commercial phase prescribed drugs company targeted on acquiring novel, plant-based, non-opioid, and sustainably derived prescription medications for people and animals with GI distress, which include chronic, debilitating diarrhea. Jaguar Animal Overall health is a tradename of Jaguar Well being. Jaguar Health’s wholly owned subsidiary, Napo Prescription drugs, Inc., focuses on building and commercializing proprietary plant-primarily based human pharmaceuticals from crops harvested responsibly from rainforest regions. Our Mytesi® (crofelemer) product is permitted by the U.S. Food and drug administration for the symptomatic reduction of noninfectious diarrhea in grown ups with HIV/AIDS on antiretroviral treatment and the only oral plant-centered prescription medicine accredited below Food and drug administration Botanical Assistance. Our crofelemer drug product or service prospect is the subject matter of the OnTarget research, an ongoing pivotal Stage 3 clinical trial for prophylaxis of diarrhea in grownup most cancers clients obtaining targeted therapy. Jaguar Well being is the the greater part shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian company founded by Jaguar Wellness in Milan, Italy in 2021 that focuses on increasing crofelemer entry in Europe.

For additional information and facts about Jaguar Health, remember to check out https://jaguar.wellness. For a lot more information about Napo Pharmaceuticals, check out www.napopharma.com.

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic reduction of noninfectious diarrhea in grownup individuals with HIV/AIDS on antiretroviral therapy (Artwork). Mytesi is not indicated for the procedure of infectious diarrhea. Rule out infectious etiologies of diarrhea prior to starting off Mytesi. If infectious etiologies are not thought of, there is a risk that clients with infectious etiologies will not get the proper treatment and their disorder may well worsen. In scientific scientific studies, the most frequent adverse reactions occurring at a amount greater than placebo were higher respiratory tract an infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and amplified bilirubin (3.1%).

See total Prescribing Information and facts at Mytesi.com. Crofelemer, the active component in Mytesi, is a botanical (plant-dependent) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has set up a sustainable harvesting application for crofelemer to make sure a high diploma of top quality and ecological integrity.

Forward-Searching Statements

Specific statements in this push launch represent “ahead-searching statements.” In some situations, you can detect ahead-on the lookout statements by terms this kind of as “may well,” “will,” “really should,” “hope,” “approach,” “goal,” “anticipate,” “could,” “intend,” “target,” “job,” “contemplate,” “consider,” “estimate,” “forecast,” “likely” or “continue on” or the negative of these conditions or other identical expressions. The forward-seeking statements in this release are only predictions. Jaguar has primarily based these ahead-hunting statements largely on its latest expectations and projections about long term activities. These ahead-searching statements communicate only as of the day of this launch and are topic to a variety of risks, uncertainties and assumptions, some of which simply cannot be predicted or quantified and some of which are over and above Jaguar’s control. Besides as demanded by relevant law, Jaguar does not approach to publicly update or revise any forward-looking statements contained herein, regardless of whether as a consequence of any new information and facts, foreseeable future events, modified circumstances or or else.


Peter Hodge
Jaguar Health and fitness, Inc.
[email protected] health

Source: Jaguar Overall health, Inc.

Look at resource edition on accesswire.com:

Related posts